SRGAP3 has been implicated as a potential oncogenic driver in low-grade gliomas, when fused with RAF1, resulting in constitutive activation of the ERK/MAPK pathway [21, 44], and altered expression of the SRGAP protein has been demonstrated in breast cancer [41]. The gene discussed is SRGAP3; the disease is breast cancer.